Literature DB >> 21849570

Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.

Kristian Angeby, Christian G Giske, Pontus Juréen, Thomas Schön, Jotam G Pasipanodya, Tawando Gumbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21849570      PMCID： PMC3165346          DOI： 10.1128/AAC.00232-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA.

Authors:  Helen D Donoghue; Mark Spigelman; Charles L Greenblatt; Galit Lev-Maor; Gila Kahila Bar-Gal; Carney Matheson; Kim Vernon; Andreas G Nerlich; Albert R Zink
Journal:  Lancet Infect Dis       Date:  2004-09       Impact factor: 25.071

Review 3.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

4.  Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism.

Authors:  Fernanda S Spies; Pedro E Almeida da Silva; Marta O Ribeiro; Maria Lucia Rossetti; Arnaldo Zaha
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

5.  Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.

Authors:  Tawanda Gumbo; Arnold Louie; Weiguo Liu; David Brown; Paul G Ambrose; Sujata M Bhavnani; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

6.  Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

Authors:  Marc Weiner; Charles Peloquin; William Burman; Chi-Cheng Luo; Melissa Engle; Thomas J Prihoda; William R Mac Kenzie; Erin Bliven-Sizemore; John L Johnson; Andrew Vernon
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

7.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  Breakpoints for susceptibility testing should not divide wild-type distributions of important target species.

Authors:  Maiken Cavling Arendrup; Gunnar Kahlmeter; Juan Luis Rodriguez-Tudela; J Peter Donnelly
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Antimicrobial susceptibility in Escherichia coli of human and avian origin--a comparison of wild-type distributions.

Authors:  M Sjölund; S Bengtsson; J Bonnedahl; J Hernandez; B Olsen; G Kahlmeter
Journal:  Clin Microbiol Infect       Date:  2009-03-02       Impact factor: 8.067

10.  Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection.

Authors:  Christopher B Ford; Philana Ling Lin; Michael R Chase; Rupal R Shah; Oleg Iartchouk; James Galagan; Nilofar Mohaideen; Thomas R Ioerger; James C Sacchettini; Marc Lipsitch; JoAnne L Flynn; Sarah M Fortune
Journal:  Nat Genet       Date:  2011-04-24       Impact factor: 38.330
View more
  4 in total

1.  New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates.

Authors:  Jotam Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2012-10       Impact factor: 5.191

2.  Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.

Authors:  Marva Seifert; Edmund Capparelli; Donald G Catanzaro; Timothy C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.

Authors:  Jansy Sarathy; Landry Blanc; Nadine Alvarez-Cabrera; Paul O'Brien; Isabela Dias-Freedman; Marizel Mina; Matthew Zimmerman; Firat Kaya; Hsin-Pin Ho Liang; Brendan Prideaux; Jillian Dietzold; Padmini Salgame; Radojka M Savic; Jennifer Linderman; Denise Kirschner; Elsje Pienaar; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Comparison between the BACTEC MGIT 960 system and the agar proportion method for susceptibility testing of multidrug resistant tuberculosis strains in a high burden setting of South Africa.

Authors:  Halima M Said; Marleen M Kock; Nazir A Ismail; Kamaldeen Baba; Shaheed V Omar; Ayman G Osman; Anwar A Hoosen; Marthie M Ehlers
Journal:  BMC Infect Dis       Date:  2012-12-22       Impact factor: 3.090
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.